The BeginNGS program will screen newborns for over 1,000 treatable genetic disorders, allowing for early interventions and potentially saving lives. The partnership with Sidra Medicine aims to advance the detection of genetic diseases and establish a new standard for preventative medicine in genomics.
The BeginNGS Consortium has welcomed Alexion, AstraZeneca Rare Disease as its first Platinum member, furthering the development of genome-informed healthcare delivery. This partnership aims to implement BeginNGS for 1,000 diseases in at least 10 countries by 2030.
A new study describes a case where long-read genomic sequencing (LRS) was used to diagnose RFX3 haplo-insufficiency syndrome in a patient with autism spectrum disorder and intellectual disability. The study highlights the potential benefits of genetic testing in psychiatric care, including expediting workups for inpatient patients.
A new study published in Nature reveals critical insights into how spina bifida develops, identifying specific steps in embryogenesis that contribute to the condition. The research also suggests a potential link between new DNA mutations and disease risk, opening the door for future treatments such as gene therapy and targeted drugs.
A new study emphasizes the importance of understanding genetic underpinnings of psychiatric disorders for mental health providers. Key findings highlight the application of genetic information in risk assessment, diagnosis, treatment selection, and patient education, while also considering ethical considerations.
The BeginNGS platform uses genome sequencing and artificial intelligence to detect rare genetic diseases in newborns, achieving a 97% reduction in false positives. This technology has the potential to save thousands of lives by providing earlier diagnoses and treatment.
A study published in JAMA Network Open found that single-locus genetic diseases were the most common cause of infant mortality, accounting for 41% of deaths. The research suggests that diagnostic whole genome sequencing may have prevented some deaths and that treatments for these conditions are available for 30% of cases.
Researchers identified a new clinical syndrome, Neuro-Ocular DAGLA-related Syndrome (NODRS), in children with termination variants in the diacylglycerol lipase alpha (DAGLA) gene. The study found that enzymatic activity was preserved despite mis-localization of the truncated protein.
A scalable prototype for newborn screening, including rapid Whole Genome Sequencing and virtual acute management guidance, has been developed to rapidly screen for several hundred genetic diseases. The system demonstrates feasibility in identifying genetic diseases with effective interventions.
A study published in Nature Communications describes the performance of GTRx, an automated disease management system that integrates rapid Whole Genome Sequencing diagnosis with analysis pipeline. The system provides clinical decision support to guide physicians in selecting optimal therapies for critically ill infants and children.
A retrospective study demonstrates that AI-powered Fabric GEM algorithm can detect over 90% of disease-causing variants in infants with rare diseases using whole-genome and whole-exome data. The algorithm also ranks specific genes associated with these variants, assisting clinicians in diagnosis.
A vast majority of doctors and parents believe genomic sequencing is beneficial for managing care in infants with diseases of unknown origin. The test reveals genetic variations responsible for the child's disease, even if results are negative.
A machine-learning system using clinical natural language processing and genome sequencing diagnose rare genetic diseases in record time, providing critical information to intensive care physicians. The automated pipeline achieved significant time-savings and concurred with expert manual interpretation in 97% of cases.